Antibody Industry Trends

The therapeutic potential of monoclonal antibodies (mAbs) has expanded dramatically over the past two decades, driven not only by advances in target discovery but also by innovations in antibody engineering. Among these, the engineering of the fragment crystallizable (Fc) domain has emerged as a pow

Biointron’s Q1 2025 annual antibody report aims to explore the events and trends of the biopharmaceutical industry in 2025 (January, February, March).

Affinity maturation is a fundamental process in adaptive immunity, enabling B cells to refine antibody specificity and enhance binding strength through iterative cycles of somatic hypermutation (SHM) and selection. This natural optimization mechanism is not only crucial for effective immune response

G protein-coupled receptors (GPCRs) and ion channels are protein families linked to a broad spectrum of diseases, known as GPCR- and ion channel-driven diseases, which arise from dysfunction in cell signaling and ion transport. GPCR-driven diseases include conditions such as cancer, metabolic disord

Six years after the emergence of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), the landscape of viral neutralization has shifted significantly. Advances in antibody therapeutics, vaccine development, and immune response understanding have reshaped our approach to combating COVID-19 a

Immunotoxins are a class of targeted therapies that consist of an antibody conjugated to a potent toxin, designed to selectively deliver the toxin to cancer cells. Unlike antibody-drug conjugates (ADCs), which use a cytotoxic payload, immunotoxins leverage bacterial or plant-derived toxins, such as Pseudomonas exotoxin A (PE), diphtheria toxin, ricin, or gelonin, to kill cancer cells directly.

Amyloidosis is a rare disease characterized by the abnormal accumulation of misfolded proteins called amyloids in various organs and tissues, leading to organ dysfunction. These protein deposits can affect the heart, kidneys, liver, nervous system, and other areas, causing symptoms such as fatigue, swelling, numbness, and organ failure.

Antibody-toxin conjugates (ATCs) are targeted therapeutic agents that combine an antibody with a potent toxin to selectively eliminate diseased cells, such as cancer cells or infected cells. These conjugates leverage the antibody’s specificity to deliver the toxin directly to target cells, minimizi

On January 24, 2025, the novel monoclonal antibody Andembry (garadacimab) was approved in Australia! The drug is now approved for routine prevention of recurrent hereditary angioedema (HAE) attacks in patients aged 12 years and older with C1-esterase inhibitor deficiency or dysfunction. Andemb

B cells are central players in both humoral and cellular immunity, traditionally recognized for their role in antibody production. However, recent research highlights their direct involvement at sites of inflammation, where they establish tissue-resident memory populations and contribute to immune responses in infection, inflammatory diseases, and cancer.

​Inhaled antibody therapies represent a promising advancement in therapeutics, particularly for treating respiratory infections. By delivering antibodies directly to the lungs via inhalation, these therapies target pathogens at the primary site of infection, potentially improving efficacy and reducing systemic side effects.

Antibody therapeutics are emerging as a promising avenue in the fight against obesity, a condition that significantly elevates the risk of cardiovascular disease, type 2 diabetes, and certain cancers.